Stock A268600 CELLIVERY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cellivery Therapeutics, Inc.

Equities

A268600

KR7268600004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 22/03/2023 GMT 		5-day change 1st Jan Change
6,680 KRW -29.91% Intraday chart for Cellivery Therapeutics, Inc. -.--% -.--%
2023 Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index CI
2021 Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion. CI

Business Summary

Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Sales per Business

KRW in Million2022Weight2023Weight Delta
Research and Development Service
100.0 %
1,425 6.2 % 18,863 100.0 % +1,223.95%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
95.3 %
21,380 92.3 % 17,979 95.3 % -15.91%
Overseas
4.7 %
1,778 7.7 % 884 4.7 % -50.29%

Managers

Managers TitleAgeSince
Dae-Woong Cho CEO
 Chief Executive Officer 56 13/03/14
Sun-Hong Kwon BRD
 Director/Board Member 50 28/03/21
Byung-Hwa Lee AUD
 Comptroller/Controller/Auditor 60 21/03/19

Members of the board

Members of the board TitleAgeSince
Dae-Woong Cho CEO
 Chief Executive Officer 56 13/03/14
Sun-Hong Kwon BRD
 Director/Board Member 50 28/03/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,667,845 31,520,791 ( 85.96 %) 0 85.67 %
Stock B 0 124,120 0 0

Shareholders

NameEquities%Valuation
Dae-Woong Cho
13.40 %
4,899,454 13.40 % 26 M ₩
Jin-bok Lee
0.5470 %
200,000 0.5470 % 1 M ₩
Sun-Hong Kwon
0.1094 %
40,000 0.1094 % 209 020 ₩
Mirae Asset Global Investments Co., Ltd.
0.004234 %
1,548 0.004234 % 8 089 ₩

Company contact information

Cellivery Therapeutics, Inc.

K-BIZ DMC Tower 189 Seongam-ro

03929, Seoul

+

http://www.cellivery.com
address Cellivery Therapeutics, Inc.(A268600)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CELLIVERY THERAPEUTICS, INC. Stock Cellivery Therapeutics, Inc.
-.--% 180M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.99% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.01% 107B
BIONTECH SE Stock BioNTech SE
-3.07% 22.22B
ARGENX SE Stock argenx SE
-0.67% 21.28B
GENMAB A/S Stock Genmab A/S
-4.64% 18.8B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.90% 17.51B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 17.17B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.82% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.05% 12.2B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A268600 Stock
  4. Company Cellivery Therapeutics, Inc.